Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme von VREDENBURGH, James J, DESJARDINS, Annick, WAGNER, Melissa, BAILEY, Leighann, BIGNER, Darell D, FRIEDMAN, Allan H, FRIEDMAN, Henry S, HERNDON, James E, MARCELLO, Jennifer, REARDON, David A, QUINN, Jennifer A, RICH, Jeremy N, SATHORNSUMETEE, Sith, GURURANGAN, Sridharan, SAMPSON, John

Volltext

Bevacizumab and daily temozolomide for recurrent glioblastoma von Desjardins, Annick, Reardon, David A., Coan, April, Marcello, Jennifer, Herndon, James E., Bailey, Leighann, Peters, Katherine B., Friedman, Henry S., Vredenburgh, James J.

Volltext

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma von VREDENBURGH, James J, DESJARDINS, Annick, FRIEDMAN, Allan H, BIGNER, Darell D, FRIEDMAN, Henry S, REARDON, David A, PETERS, Katherine B, HERNDON, James E, MARCELLO, Jennifer, KIRKPATRICK, John P, SAMPSON, John H, BAILEY, Leighann, THREATT, Stevie

Volltext

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas von DESJARDINS, Annick, REARDON, David A, SIGNER, Darell D, FRIEDMAN, Allan H, FRIEDMAN, Henry S, VREDENBURGH, James J, HERNDON, James E, MARCELLO, Jennifer, QUINN, Jennifer A, RICH, Jeremy N, SATHORNSUMETEE, Sith, GURURANGAN, Sridharan, SAMPSON, John, BAILEY, Leighann

Volltext

Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme von Vredenburgh, James J., M.D, Desjardins, Annick, M.D., FRCPC, Kirkpatrick, John P., M.D, Reardon, David A., M.D, Peters, Katherine B., M.D., Ph.D, Herndon, James E., Ph.D, Marcello, Jennifer, M.S, Bailey, Leighann, B.S, Threatt, Stevie, B.A, Sampson, John, M.D., Ph.D, Friedman, Allan, M.D, Friedman, Henry S., M.D

Volltext

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma von Lou, Emil, Peters, Katherine B., Sumrall, Ashley L., Desjardins, Annick, Reardon, David A., Lipp, Eric S., Herndon, James E., Coan, April, Bailey, Leighann, Turner, Scott, Friedman, Henry S., Vredenburgh, James J.

Volltext

Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma mult... von Vredenburgh, James J, Desjardins, Annick, Peters, Katherine B., Reardon, David A., Herndon, James Emmett, Coan, April D., Kirkpatrick, John, Bailey, Leighann, Threatt, Stevie, Sampson, John Howard, Friedman, Allan H., Friedman, Henry S.

Volltext

The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM) von Friedman, Henry S., Desjardins, Annick, Peters, Katherine B., Reardon, David A., Kirkpatrick, John, Herndon, James Emmett, Coan, April D., Bailey, Leighann, Sampson, John Howard, Friedman, Allan H., Vredenburgh, James J

Volltext